Related Experiment Video

Updated: Apr 17, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Targeted treatments for multiple myeloma: specific role of carfilzomib

Dhivya Sugumar1, Jesse Keller2, Ravi Vij2

  • 1Department of Internal Medicine, St Mary's Health Center, Washington University in St Louis, St Louis, USA.

Pharmacogenomics and Personalized Medicine
|February 19, 2015
PubMed

Insights

Carfilzomib, a proteasome inhibitor, is increasingly used for multiple myeloma treatment. Growing evidence supports its efficacy as a standalone therapy and in combination regimens.

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Carfilzomib is a selective, irreversible proteasome inhibitor.
  • It was first approved in 2012 for relapsed and refractory multiple myeloma.
  • Numerous clinical studies have explored its use in various multiple myeloma settings.

Purpose of the Study:

  • To review the role of carfilzomib in multiple myeloma treatment.
  • To discuss its mechanism of action, pharmacokinetics, and clinical management.
  • To consolidate growing evidence supporting its therapeutic applications.

Main Methods:

  • Review of Phase II and Phase III clinical studies.
  • Analysis of pharmacokinetic data.
  • Evaluation of clinical management strategies.

Main Results:

  • Carfilzomib demonstrates efficacy as single-agent therapy.
  • Combination therapies with carfilzomib show promising results.
  • Ongoing Phase III studies are expected to provide further data.

Conclusions:

  • Carfilzomib is a valuable therapeutic option for multiple myeloma.
  • Its role is expanding in both relapsed/refractory and newly diagnosed patients.
  • Further research continues to define its optimal use in combination therapies.
Keywords:
novel agentsproteasome inhibitorrelapsed and refractorytargeted therapy

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K